ذهان منبه
مراجع

1 2  "Adderall XR Prescribing Information" (PDF). United States Food and Drug Administration. Shire US Inc. ديسمبر 2013. مؤرشف من الأصل (PDF) في 2021-06-22. اطلع عليه بتاريخ 2013-12-30. Treatment-emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without prior history of psychotic illness or mania can be caused by stimulants at usual doses. ... In a pooled analysis of multiple short-term, placebo controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.
1 2  Shoptaw، Steven J؛ Kao، Uyen؛ Ling، Walter (21 يناير 2009). "Treatment for amphetamine psychosis". Cochrane Database of Systematic Reviews ع. 1: CD003026. DOI:10.1002/14651858.CD003026.pub3. PMC:7004251. PMID:19160215.
1 2  Mosholder AD، Gelperin K، Hammad TA، Phelan K، Johann-Liang R (فبراير 2009). "Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children". Pediatrics. ج. 123 ع. 2: 611–616. DOI:10.1542/peds.2008-0185. PMID:19171629. S2CID:22391693.
↑  Greening، David W.؛ Notaras، Michael؛ Chen، Maoshan؛ Xu، Rong؛ Smith، Joel D.؛ Cheng، Lesley؛ Simpson، Richard J.؛ Hill، Andrew F.؛ van den Buuse، Maarten (10 ديسمبر 2019). "Chronic methamphetamine interacts with BDNF Val66Met to remodel psychosis pathways in the mesocorticolimbic proteome". Molecular Psychiatry. DOI:10.1038/s41380-019-0617-8. PMID:31822818. S2CID:209169489.
1 2 3  Shoptaw SJ، Kao U، Ling W (2009). "Treatment for amphetamine psychosis (Review)". Cochrane Database of Systematic Reviews. ج. 2009 ع. 1: 1. DOI:10.1002/14651858.cd003026.pub3. PMC:7004251. PMID:19160215.
↑  McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006;101(10):1473–8.
↑  Dore G، Sweeting M (2006). "Drug-induced psychosis associated with crystalline methamphetamine". Australasian Psychiatry. ج. 14 ع. 1: 86–9. DOI:10.1080/j.1440-1665.2006.02252.x. PMID:16630206. S2CID:196398062.
↑  Srisurapanont M، Ali R، Marsden J، Sunga A، Wada K، Monteiro M (2003). "Psychotic symptoms in methamphetamine psychotic in-patients". International Journal of Neuropsychopharmacology. ج. 6 ع. 4: 347–52. DOI:10.1017/s1461145703003675. PMID:14604449.
1 2  Sato M، Numachi Y، Hamamura T (1992). "Relapse of paranoid psychotic state in methamphetamine model of schizophrenia". Schizophrenia Bulletin. ج. 18 ع. 1: 115–22. DOI:10.1093/schbul/18.1.115. PMID:1553491.
↑  Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (ط. 2nd). New York: Oxford University Press. ص. 329.
↑  Yui K، Ikemoto S، Goto K (2002). "Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis". Annals of the New York Academy of Sciences. ج. 965 ع. 1: 292–304. Bibcode:2002NYASA.965..292Y. DOI:10.1111/j.1749-6632.2002.tb04171.x. PMID:12105105. S2CID:25830663.
↑  Alan F. Schatzberg؛ Charles B. Nemeroff (2009). The American Psychiatric Publishing Textbook of Psychopharmacology. The American Psychiatric Publishing. ص. 847–48. ISBN:978-1-58562-309-9. مؤرشف من الأصل في 2021-08-02.
↑  Chen CK، Lin SK، Pak CS، Ball D، Loh EW، Murray RM (2005). "Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis". American Journal of Medical Genetics Part B. ج. 136 ع. 1: 87–91. DOI:10.1002/ajmg.b.30187. PMID:15892150. S2CID:25135637.
↑  McIver C, McGregor C, Baigent M, Spain D, Newcombe D, Ali R. Guidelines for the medical management of patients with methamphetamine-induced psychosis. Drug and Alcohol Services: South Australia 2006.
↑  Sarampote CS، Efron LA، Robb AS، Pearl PL، Stein MA (2002). "Can stimulant rebound mimic pediatric bipolar disorder?". J Child Adolesc Psychopharmacol. ج. 12 ع. 1: 63–7. DOI:10.1089/10445460252943588. PMID:12014597.
↑  American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
↑  Hegerl U، Sander C، Olbrich S، Schoenknecht P (أغسطس 2006). "Are psychostimulants a treatment option in mania?". Prog Neuropsychopharmacol Biol Psychiatry. ج. 30 ع. 6: 1097–102. DOI:10.1016/j.pnpbp.2006.04.016. PMID:16740350. S2CID:13239942.
↑  Brady KT، Lydiard RB، Malcolm R، Ballenger JC (1991). "Cocaine-induced psychosis". J Clin Psychiatry. ج. 52 ع. 12: 509–512. PMID:1752853.
1 2 3  Thirthalli J.؛ Vivek B. (2006). "Psychosis Among Substance Users". Curr Opin Psychiatry. ج. 19 ع. 3: 239–245. DOI:10.1097/01.yco.0000218593.08313.fd. PMID:16612208. S2CID:13350537. مؤرشف من الأصل في 2020-11-11.
↑  Elliott A.؛ Mahmood T.؛ Smalligan R. D. (2012). "Cocaine Bugs: A Case Report of Cocaine-Induced Delusions of Parasitosis". The American Journal on Addictions. ج. 21 ع. 2: 180–181. DOI:10.1111/j.1521-0391.2011.00208.x. PMID:22332864.
↑  DiSCLAFANI؛ وآخرون (1981). "Drug-induced psychosis: Emergency diagnosis and management". Psychosomatics. ج. 22 ع. 10: 845–855. DOI:10.1016/s0033-3182(81)73092-5. PMID:7313045.
↑  Robins، Meridith T.؛ Blaine، Arryn T.؛ Ha، Jiwon E.؛ Brewster، Amy L.؛ Van Rijn، Richard M. (2019). "Repeated Use of the Psychoactive Substance Ethylphenidate Impacts Neurochemistry and Reward Learning in Adolescent Male and Female Mice". Frontiers in Neuroscience. ج. 13: 124. DOI:10.3389/fnins.2019.00124. PMC:6389692. PMID:30837836.{{استشهاد بدورية محكمة}}:  صيانة الاستشهاد: دوي مجاني غير معلم (link)
↑  McLaughlin، G.؛ Morris، N.؛ Kavanagh، P. V.؛ Power، J. D.؛ Dowling، G.؛ Twamley، B.؛ O'Brien، J.؛ Hessman، G.؛ Murphy، B.؛ Walther، D.؛ Partilla، J. S.؛ Baumann، M. H.؛ Brandt، S. D. (2017). "Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo- and (±)-erythro- diastereomers". Drug Testing and Analysis. ج. 9 ع. 3: 347–357. DOI:10.1002/dta.2167. PMC:5378611. PMID:28103426.
↑  Markowitz، J. S.؛ Zhu، H. J.؛ Patrick، K. S. (2013). "Isopropylphenidate: An ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability". Journal of Child and Adolescent Psychopharmacology. ج. 23 ع. 10: 648–54. DOI:10.1089/cap.2013.0074. hdl:2027.42/140321. PMID:24261661.
↑  Morton WA، Stockton GG (2000). "Methylphenidate abuse and psychiatric side effects". Prim Care Companion J Clin Psychiatry. ج. 2 ع. 5: 159–64. DOI:10.4088/pcc.v02n0502. PMC:181133. PMID:15014637.
↑  Spensley J، Rockwell D (أبريل 1972). "Psychosis during methylphenidate Abuse". New England Journal of Medicine. ج. 286 ع. 16: 880–1. DOI:10.1056/NEJM197204202861607. PMID:5061074.
↑  Robertson، Roy (2017). "Prolonged mental health effects of ethylphenidate beyond cessation of use". Addiction. ج. 112 ع. 1: 183–184. DOI:10.1111/add.13630. PMID:27936504.
↑  McLaughlin، Gavin؛ Morris، Noreen؛ Kavanagh، Pierce V.؛ Power، John D.؛ Dowling، Geraldine؛ Twamley، Brendan؛ O'Brien، John؛ Hessman، Gary؛ Murphy، Brian؛ Walther، Donna؛ Partilla، John S.؛ Baumann، Michael H.؛ Brandt، Simon D. (مارس 2017). "Analytical characterization and pharmacological evaluation of the new psychoactive substance 4‐fluoromethylphenidate (4F‐MPH) and differentiation between the (±)‐threo and (±)‐erythro diastereomers". Drug Testing and Analysis. ج. 9 ع. 3: 347–357. DOI:10.1002/dta.2167. PMC:5378611. PMID:28103426.
↑  Markowitz، John S.؛ Zhu، Hao-Jie؛ Patrick، Kennerly S. (ديسمبر 2013). "Isopropylphenidate: An Ester Homolog of Methylphenidate with Sustained and Selective Dopaminergic Activity and Reduced Drug Interaction Liability". Journal of Child and Adolescent Psychopharmacology. ج. 23 ع. 10: 648–654. DOI:10.1089/cap.2013.0074. hdl:2027.42/140321. PMID:24261661.
↑  Hedges، D. W.؛ F. L. Woon؛ S. P. Hoopes (سبتمبر 2009). "Caffeine-induced psychosis". CNS Spectrums. ج. 14 ع. 3: 127–9. DOI:10.1017/S1092852900020101. PMID:19407709. S2CID:32188625.
↑  Cerimele، Joseph M.؛ Stern، Adam P.؛ Jutras-Aswad، Didier (مارس 2010). "Psychosis Following Excessive Ingestion of Energy Drinks in a Patient With Schizophrenia". American Journal of Psychiatry. ج. 167 ع. 3: 353. DOI:10.1176/appi.ajp.2009.09101456. PMID:20194494. S2CID:5832823. مؤرشف من الأصل في 2021-04-29.
↑  Broderick، P.؛ Benjamin، A. B. (2004). "Caffeine and psychiatric symptoms: A review". The Journal of the Oklahoma State Medical Association. ج. 97 ع. 12: 538–542. PMID:15732884.
↑  "White Paper Report on Excited Delirium Syndrome" نسخة محفوظة 22 يوليو 2018 على موقع واي باك مشين. , ACEP Excited Delirium Task Force, American College of Emergency Physicians, 10 September 2009 "نسخة مؤرشفة" (PDF). مؤرشف من الأصل في 2018-07-22. اطلع عليه بتاريخ 2021-08-02.{{استشهاد ويب}}:  صيانة الاستشهاد: BOT: original URL status unknown (link)
↑  Murrie، Benjamin؛ Lappin، Julia؛ Large، Matthew؛ Sara، Grant (16 أكتوبر 2019). "Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis". Schizophrenia Bulletin. ج. 46 ع. 3: 505–516. DOI:10.1093/schbul/sbz102. PMC:7147575. PMID:31618428.
↑  Penders، T. M.؛ Lang، M. C.؛ Pagano، J. J.؛ Gooding، Z. S. (2013). "Electroconvulsive therapy improves persistent psychosis after repeated use of methylenedioxypyrovalerone ("bath salts")". The Journal of ECT. ج. 29 ع. 4: e59-60. DOI:10.1097/YCT.0b013e3182887bc2. PMID:23609518. S2CID:45842375.
| 0 | 1 |
| --- | --- |
التصنيفات الطبية:  رموز المراجعة التاسعة للتصنيف الدولي للأمراض (ICD-9): 292.1  رموز المراجعة العاشرة للتصنيف الدولي للأمراض (ICD-10): F15.5  
المعرفات الخارجية:  الطب الرقمي (eMedicine): 289973  
بوابة صيدلة
بوابة طب